Recommended Reading

By Kate Greenwood
In Drugs & Devices
Oct 30th, 2014
0 Comments
Cross-Posted at Bill of Health As I have blogged about before, last year, in Kaiser v. Pfizer, the First Circuit joined the handful of courts to have approved a causal chain of injury running from a pharmaceutical company’s fraudulent promotion, through the prescribing decisions of thousands of individual physicians, to the prescriptions for which a third-party [&helli...
By Tara Adams Ragone
In Recommended Reading
Apr 25th, 2014
0 Comments
This white paper reports on a convener session held by AHLA’s public interest committee in October 2013.  The session brought together a diverse array of individuals from government, industry, providers, patient advocates, and academia, including Seton Hall Law Professor John V. Jacobi, to discuss the federal Anti-Kickback Statute and Civil Money Penalty Law’s prohibit...
By Tara Adams Ragone
In Recommended Reading
Apr 23rd, 2014
1 Comment
As the ACA’s first open enrollment period closes, a trio of articles in the recent Houston Law Review offers critical analyses of what health reform has accomplished and important reminders of what remains to be done: 1. Mark A. Hall’s Frankel Lecture, Evaluating the Affordable Care Act: The Eye of the Beholder, seeks to provide […]...
By Kate Greenwood
In Recommended Reading
Jan 8th, 2014
0 Comments
I put Karen Syma Czapanskiy’s article Special Kids, Special Parents, Special Education, which is forthcoming early this year in the Michigan Journal of Law Reform, on my To Read list when she  blogged about it (here and here) back in August.  This week, I finally read it, and I am glad I did.  In the article, Professor Czapanskiy sets […]...
By Kate Greenwood
In Drugs & Devices
Oct 31st, 2013
0 Comments
I highly recommend Benjamin Roin’s two most recent articles to anyone with an interest in the incentives for innovation set by our current, intellectual property-based system.  Roin’s articles will be of particular interest to those interested in the incentives for developing new drugs and for discovering new uses for existing drugs. In Intellectual Propert...